Isoray, Inc. (ISR) |
| 0.384 0 (0%) 02-17 16:00 |
| Open: | 0.3724 |
| High: | 0.39 |
| Low: | 0.3613 |
| Volume: | 145,041 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | New York Stock Exchange Arca |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 19.14 |
| Resistance 1: | 17.41 |
| Pivot price: | 15.65 |
| Support 1: | 14.62 |
| Support 2: | 12.16 |
| 52w High: | 0.45 |
| 52w Low: | 0.19 |
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.
| EPS | 4.430 |
| Book Value | 1.750 |
| PEG Ratio | 0.00 |
| Gross Profit | 3886.190 |
| Profit Margin (%) | 98.94 |
| Operating Margin (%) | 54.97 |
| Return on Assets (ttm) | 3.9 |
| Return on Equity (ttm) | 31.2 |
Wed, 08 Feb 2023
Medtech companies merge to form Perspective Therapeutics - Corridor Business Journal
Mon, 06 Feb 2023
Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine - Business Wire
Tue, 18 Oct 2022
Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT - Business Wire
Mon, 14 Jun 2021
Isoray raises $50M to expand Cesium-131 cancer treatments - Tri-Cities Area Journal of Business
Tue, 25 Sep 2018
IsoRay reports beats on fiscal 4Q and full year revenue, but earnings per share loss widens slightly - Proactive Investors
Thu, 09 Mar 2017
IsoRay Announces Final Court Approval of Class Action Settlement - PR Newswire
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |